Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study

Effect of Anti-Interleukin-6 Agents on Psychopathology in a Sample of Patients with Post-COVID-19 Syndrome: An Observational Study

Interleukin 6 (IL-6) receptor inhibitors tocilizumab and sarilumab have recently been approved for severe coronavirus disease 2019 (COVID-19). They also affect mood, even though their effect on the post-COVID-19 syndrome-related psychopathology still has to be investigated. The aim of this study was...

Full description

Bibliographic Details
Main Authors: Alessio Simonetti, Antonio Restaino, Evelina Bernardi, Ottavia Marianna Ferrara, Stella Margoni, Antonio Maria D’Onofrio, Federica Ranieri, Delfina Janiri, Vincenzo Galluzzo, Matteo Tosato, Georgios D. Kotzalidis, Francesco Landi, Gabriele Sani
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Brain Sciences
Subjects:
COVID-19
post-COVID-19 syndrome
Il-6
bevacizumab
sarilumab
Online Access:https://www.mdpi.com/2076-3425/14/1/47

Internet

https://www.mdpi.com/2076-3425/14/1/47

Similar Items